Paul Stoffels, J&J CSO (Andrew Harnik/AP Images)
October 12, 2021 07:41 AM EDTUpdated 04:55 PM
People

J&J sci­ence lead Paul Stof­fels set to re­tire amid brain trust shake­up at world's largest drug­mak­er

Kyle Blankenship

Paul Stof­fels, the sci­en­tif­ic lead be­hind J&J’s re­fresh of its hal­lowed Janssen unit and the cre­ation of the com­pa­ny’s sin­gle-shot Covid-19 vac­cine, will re­tire at …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times